📊 SRZNW Key Takeaways
Is Surrozen, Inc./DE (SRZNW) a Good Investment?
Surrozen exhibits severe balance sheet deterioration with negative stockholders' equity of -$187.8M, indicating technical insolvency. The company burns ~$30M annually with only $3.5M in revenue and no growth trajectory, creating an unsustainable cash situation despite adequate near-term liquidity. Fundamental viability depends entirely on external capital raises or transformative clinical outcomes, both representing high-risk catalysts.
Why Buy Surrozen, Inc./DE Stock? SRZNW Key Strengths
- Cash position of $89.2M provides 2-3 years of runway at current burn rate
- Strong liquidity ratios (9.22x current/quick) ensure near-term operational continuity
- Active insider participation (11 Form 4 filings) suggests management engagement with company direction
SRZNW Stock Risks: Surrozen, Inc./DE Investment Risks
- Negative stockholders' equity of -$187.8M indicates technical insolvency and balance sheet impairment
- Operating cash burn of -$30.2M annually is unsustainable without external financing or revenue acceleration
- Minimal revenue of $3.5M with 0% YoY growth provides no evidence of commercial viability or path to profitability
- Liabilities of $286.5M exceed assets by $187.8M, creating significant capital structure risk and dilution potential
- Negative margins across all profitability metrics (-6960.8% net margin, -1210.6% operating margin)
Key Metrics to Watch
- Stockholders' equity trend - movement toward positive equity is critical for solvency
- Cash burn rate and cash runway - any material change impacts survival timeline
- Revenue growth acceleration - evidence of commercial traction or partnership deals
- Operating cash flow trajectory - path to sustainable cash generation
Surrozen, Inc./DE (SRZNW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.22x current ratio provides a solid financial cushion.
SRZNW Profit Margin, ROE & Profitability Analysis
SRZNW vs Healthcare Sector: How Surrozen, Inc./DE Compares
How Surrozen, Inc./DE compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Surrozen, Inc./DE Stock Overvalued? SRZNW Valuation Analysis 2026
Based on fundamental analysis, Surrozen, Inc./DE has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Surrozen, Inc./DE Balance Sheet: SRZNW Debt, Cash & Liquidity
SRZNW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Surrozen, Inc./DE's revenue has declined by 15% over the 5-year period, indicating business contraction. The most recent EPS of $-21.67 indicates the company is currently unprofitable.
SRZNW Revenue Growth, EPS Growth & YoY Performance
SRZNW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $983.0K | -$1.4M | $-0.44 |
| Q2 2025 | N/A | $12.8M | $0.85 |
| Q1 2025 | N/A | -$8.8M | $-4.24 |
| Q3 2024 | N/A | -$1.4M | $-0.44 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Surrozen, Inc./DE Dividends, Buybacks & Capital Allocation
SRZNW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Surrozen, Inc./DE (CIK: 0001824893)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SRZNW
What is the AI rating for SRZNW?
Surrozen, Inc./DE (SRZNW) has an AI rating of STRONG SELL with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SRZNW's key strengths?
Claude: Cash position of $89.2M provides 2-3 years of runway at current burn rate. Strong liquidity ratios (9.22x current/quick) ensure near-term operational continuity.
What are the risks of investing in SRZNW?
Claude: Negative stockholders' equity of -$187.8M indicates technical insolvency and balance sheet impairment. Operating cash burn of -$30.2M annually is unsustainable without external financing or revenue acceleration.
What is SRZNW's revenue and growth?
Surrozen, Inc./DE reported revenue of $3.5M.
Does SRZNW pay dividends?
Surrozen, Inc./DE does not currently pay dividends.
Where can I find SRZNW SEC filings?
Official SEC filings for Surrozen, Inc./DE (CIK: 0001824893) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SRZNW's EPS?
Surrozen, Inc./DE has a diluted EPS of $-32.37.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SRZNW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Surrozen, Inc./DE has a STRONG SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SRZNW stock overvalued or undervalued?
Valuation metrics for SRZNW: ROE of N/A (sector avg: 15%), net margin of -6,960.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SRZNW stock in 2026?
Our dual AI analysis gives Surrozen, Inc./DE a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SRZNW's free cash flow?
Surrozen, Inc./DE's operating cash flow is $-30.2M, with capital expenditures of $128.0K. FCF margin is -873.5%.
How does SRZNW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -6,960.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 9.22 (avg: 2).